[ Pobierz całość w formacie PDF ]
prediction of polypeptide aggregation propensity. Sci 94:918 927.
Curr Opin Chem Biol 10:437 444. 157. Gillespie DT. 2007. Stochastic simulation of
144. Cottingham MG, Hollinshead MS, Vaux DJT. chemical kinetics. Annu Rev Phys Chem 58:35 55.
2002. Amyloid fibril formation by a synthetic pep- 158. Gibson TJ, Murphy RM. 2005. Design of peptidyl
tide from a region of human acetylcholinesterase compounds that affect beta-amyloid aggregation:
that is homologous to the Alzheimer s amyloid- Importance of surface tension and context. Bio-
beta peptide. Biochemistry 41:13539 13547. chemistry 44:8898 8907.
145. Goldsbury C, Goldie K, Pellaud J, Seelig J, Frey P, 159. Kim JR, Gibson TJ, Murphy RM. 2006. Predicting
Muller SA, Kistler J, Cooper GJS, Aebi U. 2000. solvent and aggregation effects of peptides using
Amyloid fibril formation from full-length and frag- group contribution calculations. Biotechnol Prog
ments of amylin. J Struct Biol 130:352 362. 22:605 608.
146. Lee CC, Walters RH, Murphy RM. 2007. Reconsi- 160. Doig AJ. 2007. Peptide inhibitors of beta-amyloid
dering the mechanism of polyglutamine peptide aggregation. Curr Opin Drug Discov Devel
aggregation. Biochemistry 46:12810 12820. 10:533 539.
147. Plaza del Pino IM, Ibarra-Molero B, Sanchez-Ruiz 161. de Groot NS, Aviles FX, Vendrell J, Ventura S.
JM. 2000. Lower kinetic limit to protein thermal 2006. Mutagenesis of the central hydrophobic
stability: A proposal regarding protein stability in cluster in A beta 42 Alzheimer s pepticle Side-
vivo and its relation with misfolding diseases. chain properties correlate with aggregation pro-
Proteins Struct Funct Genet 40:58 70. pensities. FEBS J 273:658 668.
148. Yoshioka S, Aso Y, Izutsu K-I, Kojima S. 1994. 162. Murzin AG, Brenner SE, Hubbard T, Chothia C.
Is stability prediction possible for protein drugs? 1995. Scop A structural classification of proteins
Denaturation kinetics of beta -galactosidase in database for the investigation of sequences and
solution. Pharm Res 11:1721 1725. structures. J Mol Biol 247:536 540.
149. Yoshioka S, Izutsu K, Aso Y, Takeda Y. 1991. 163. Tartaglia GG, Cavalli A, Pellarin R, Caflisch A.
Inactivation kinetics of enzyme pharmaceuticals 2004. The role of aromaticity, exposed surface, and
in aqueous solution. Pharm Res 8:480 484. dipole moment in determining protein aggregation
150. Seefeldt MB, Kim YS, Tolley KP, Seely J, Carpen- rates. Protein Sci 13:1939 1941.
ter JF, Randolph TW. 2005. High-pressure studies 164. Chiti F, Stefani M, Taddei N, Ramponi G, Dobson
of aggregation of recombinant human interleukin- CM. 2003. Rationalization of the effects of muta-
1 receptor antagonist: Thermodynamics, kinetics, tions on peptide and protein aggregation rates.
and application to accelerated formulation Nature 424:805 808.
studies. Protein Sci 14:2258 2266. 165. Trovato A, Maritan A, Seno F. 2007. Aggregation
151. Gomez J, Hilser VJ, Xie D, Freire E. 1995. The of natively folded proteins: A theoretical approach.
heat capacity of proteins. Proteins Struct Funct J Phys Condens Mat 19:285221/1-10.
Genet 22:404 412. 166. Nelson R, Sawaya MR, Balbirnie M, Madsen AO,
152. Graziano G, Catanzano F, Barone G. 1998. Pre- Riekel C, Grothe R, Eisenberg D. 2005. Structure
diction of the heat capacity change on thermal of the cross-beta spine of amyloid-like fibrils. Nat-
denaturation of globular proteins. Thermochim ure 435:773 778.
Acta 321:23 31. 167. Kuhlman B, Baker D. 2000. Native protein
153. Milardi D, la Rosa C, Fasone S, Grasso D. 1997. sequences are close to optimal for their structures.
An alternative approach in the structure-based Proc Natl Acad Sci USA 97:10383 10388.
DOI 10.1002/jps JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 98, NO. 4, APRIL 2009
[ Pobierz całość w formacie PDF ]